Share-based Payment Arrangement, Expense in USD of RELMADA THERAPEUTICS, INC. from Q3 2013 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Relmada Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q3 2013 to Q1 2025.
  • Relmada Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending March 31, 2025 was $4.48M, a 46% decline year-over-year.
  • Relmada Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $30.2M, a 31.1% decline from 2023.
  • Relmada Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $43.8M, a 0.87% decline from 2022.
  • Relmada Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $44.2M, a 9.14% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)

RELMADA THERAPEUTICS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $4.48M -$3.82M -46% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-12
Q1 2024 $8.3M -$3.06M -26.9% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-12
Q1 2023 $11.4M -$576K -4.83% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q1 2022 $11.9M +$6.08M +104% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q1 2021 $5.85M +$812K +16.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q1 2020 $5.04M +$4.64M +1177% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-12
Q1 2019 $395K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
Q3 2018 $153K +$83.9K +122% Jul 1, 2018 Sep 30, 2018 10-Q 2018-11-13
Q3 2017 $601K $68.9K -$103K -60% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 $705K $292K -$67.5K -18.8% Apr 1, 2017 Jun 30, 2017 10-K 2018-09-28
Q1 2017 $772K $109K -$168K -60.8% Jan 1, 2017 Mar 31, 2017 10-Q 2017-05-15
Q4 2016 $940K $132K -$156K -54.1% Oct 1, 2016 Dec 31, 2016 10-Q 2017-02-10
Q3 2016 $1.1M $172K -$111K -39.3% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-14
Q2 2016 $1.21M $359K +$163K +82.5% Apr 1, 2016 Jun 30, 2016 10-K 2017-09-28
Q1 2016 $1.04M $277K +$32.7K +13.4% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-15
Q4 2015 $1.01M $288K +$89.4K +45.1% Oct 1, 2015 Dec 31, 2015 10-Q 2017-02-10
Q3 2015 $923K $284K +$126K +79.4% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-10
Q2 2015 $797K $197K Apr 1, 2015 Jun 30, 2015 10-K 2016-09-09
Q1 2015 $244K +$178K +273% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-09
Q4 2014 $198K Oct 1, 2014 Dec 31, 2014 10-Q 2016-02-05
Q3 2014 $158K +$158K Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-06
Q1 2014 $65.4K Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-15
Q3 2013 $0 Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-07

RELMADA THERAPEUTICS, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $30.2M -$13.6M -31.1% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-27
2023 $43.8M -$384K -0.87% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-27
2022 $44.2M +$3.7M +9.14% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-19
2021 $40.5M +$19.7M +94.9% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-23
2020 $20.8M +$17.6M +556% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-25
2019 $3.17M +$2.65M +511% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-24
2018 $518K -$187K -26.5% Jul 1, 2017 Jun 30, 2018 10-KT 2020-03-26
2017 $705K -$503K -41.6% Jul 1, 2016 Jun 30, 2017 10-K 2018-09-28
2016 $1.21M +$410K +51.5% Jul 1, 2015 Jun 30, 2016 10-K 2017-09-28
2015 $797K Jul 1, 2014 Jun 30, 2015 10-K 2016-09-09
2013 $382K Jan 1, 2013 Dec 31, 2013 10-K 2015-09-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.